Phospho-TOP2A (S1525) Antibody

What is TOP2A and why is phosphorylation at S1525 significant?

DNA topoisomerase 2-alpha (TOP2A) is a 174 kDa nuclear enzyme that resolves DNA topological problems by creating transient double-strand breaks during replication and cell division. Phosphorylation of TOP2A at serine 1525 is particularly significant as it:

• Occurs in a cell cycle-dependent manner, particularly during G2/M phase

• Regulates the timing of TOP2A recruitment to centromeres

• Is targeted by multiple kinases including CDC7/DBF4, PLK1, CKII, and p38γ (MAPK12)

• Functions in the G2/M decatenation checkpoint mechanisms

The C-terminal domain where S1525 is located (within the ChT region, amino acids 1500-1531) is considered intrinsically disordered and plays important regulatory roles despite being less studied than other TOP2A domains .

What applications are Phospho-TOP2A (S1525) antibodies validated for?

According to multiple antibody suppliers' technical information, Phospho-TOP2A (S1525) antibodies are validated for:

Most commercially available antibodies are rabbit polyclonal antibodies generated using synthetic peptides derived from human TOP2A around the phosphorylation site of Ser1525 (typically amino acids 1482-1531) .

How should Phospho-TOP2A (S1525) antibody be stored and handled?

For optimal performance and longevity:

• Store the antibody at -20°C upon receipt

• Avoid repeated freeze-thaw cycles by preparing small working aliquots

• Most formulations contain 50% glycerol, 0.5% BSA, and 0.02% sodium azide in PBS buffer

• The antibody remains stable for up to 1 year when properly stored

• When working with the antibody, maintain cold chain practices during experiments

• For western blotting applications, blocking with 5% non-fat milk or BSA is typically recommended

How does phosphorylation at S1525 affect TOP2A recruitment to centromeres and what are the implications for experimental design?

Phosphorylation at S1525, along with S1213, critically regulates the timing of TOP2A recruitment to centromeres. Research by Gonzalez et al. demonstrated that:

• The phospho-deficient S1213A/S1525A TOP2A mutant shows increased centromeric occupancy in early S-phase compared to wild-type TOP2A

• This mimics the effect observed when CDC7 kinase (Dbf4-dependent kinase, DDK) is depleted

• The phospho-mimetic S1213D/S1525D mutant behaves similarly to wild-type TOP2A

Experimental considerations:

• When designing experiments to study centromeric functions of TOP2A, researchers should consider the phosphorylation status at S1525

• For accurate interpretation, time-course experiments capturing different cell cycle phases are recommended

• Using specific inhibitors of CDC7/DDK (e.g., XL413) can help validate phosphorylation-dependent recruitment mechanisms

• When expressing TOP2A mutants, be aware that S1525A substitutions may lead to higher expression levels than wild-type protein, potentially confounding interpretation of results

What is the relationship between TOP2A S1525 phosphorylation status and cancer progression?

Several studies have investigated TOP2A expression and phosphorylation status in various cancers:

Methodological considerations for cancer research:

• When analyzing clinical samples, consider combining phospho-specific detection with total TOP2A assessment for comprehensive analysis

• For prognostic studies, correlation with patient outcomes requires careful statistical analysis and sufficient sample sizes

• When examining TOP2A phosphorylation in cancer cell lines, cell cycle synchronization may be necessary to control for cell cycle-dependent phosphorylation patterns

• Consider using phosphatase inhibitors during sample preparation to preserve phosphorylation status

How can researchers distinguish between specific S1525 phosphorylation and other phosphorylation events on TOP2A?

TOP2A contains multiple phosphorylation sites with different functional implications. To specifically study S1525 phosphorylation:

• Antibody validation is crucial:

  • Confirm specificity using phosphatase-treated samples as negative controls

  • Use S1525A mutant-expressing cells as additional controls

  • Consider peptide competition assays with phosphorylated and non-phosphorylated peptides

• Technical approaches:

  • Combine phospho-specific western blotting with phosphatase treatment experiments

  • Use mass spectrometry-based approaches for comprehensive phosphorylation mapping

  • Consider proximity ligation assays (PLA) to detect specific phosphorylation events in situ

• Interpreting complex phosphorylation patterns:

  • TOP2A is subject to multiple phosphorylation events (S1106, S1213, S1374, S1377, S1525, etc.)

  • Different kinases target specific sites: CDC7/DBF4, PLK1, CKII, and p38γ have all been implicated in S1525 phosphorylation

  • Cell cycle phase must be considered when interpreting results, as phosphorylation patterns change throughout the cell cycle

What methodological approaches can be used to study the functional consequences of S1525 phosphorylation?

To investigate how S1525 phosphorylation affects TOP2A function:

• Site-directed mutagenesis approaches:

  • Generate phospho-deficient (S1525A) and phospho-mimetic (S1525D/E) mutants

  • Evaluate effects on DNA binding, catalytic activity, and protein localization

  • Research shows S1525A does not inhibit DNA binding or catalytic activity but affects recruitment timing

• Enzymatic activity assays:

  • Decatenation assays to measure TOP2A activity

  • DNA relaxation assays to assess functional consequences

  • Cleavage complex formation assays with TOP2A poisons

• Cell-based functional assays:

  • Cell cycle progression analysis using flow cytometry

  • Chromosome segregation defect assessment

  • DNA damage response evaluation

  • Centromere recruitment timing analysis using time-lapse microscopy

• Protein-protein interaction studies:

  • Identify phosphorylation-dependent binding partners

  • Evaluate changes in complex formation throughout the cell cycle

  • Assess impact on nuclear localization and chromatin association

How should researchers design experiments to study the relationship between TOP2A S1525 phosphorylation and the DNA damage response?

TOP2A plays crucial roles in DNA damage responses, and its phosphorylation status can influence these processes:

• Experimental design considerations:

  • Include appropriate DNA damaging agents (etoposide, doxorubicin, radiation)

  • Control for cell cycle effects using synchronization techniques

  • Consider checkpoint activation status when interpreting results

• Methodological approaches:

  • Monitor γH2AX foci formation in the presence of wild-type vs. S1525A/D TOP2A

  • Assess checkpoint activation (CHK1/CHK2 phosphorylation)

  • Evaluate TOP2A-DNA adduct formation using TARDIS assay (Trapped in Agarose DNA Immunostaining)

  • Study the recruitment kinetics of repair factors in the context of different TOP2A phosphorylation states

• Data interpretation challenges:

  • Distinguish between direct effects of S1525 phosphorylation and secondary consequences

  • Consider potential compensatory mechanisms in genetic models

  • Account for the influence of other post-translational modifications

What are the common technical issues when using Phospho-TOP2A (S1525) antibodies and how can they be addressed?

Several technical challenges may arise when working with phospho-specific antibodies:

• Loss of phosphorylation signal:

  • Always include phosphatase inhibitors in lysis buffers (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Process samples quickly and maintain cold temperatures

  • Avoid multiple freeze-thaw cycles of protein samples

• Background or non-specific signals:

  • Optimize blocking conditions (5% BSA often works better than milk for phospho-epitopes)

  • Titrate antibody concentration carefully (1:500-1:2000 for WB is typical)

  • Consider more stringent washing conditions (higher salt concentration)

  • Pre-absorb antibody with non-phosphorylated peptide if available

• Tissue-specific optimization:

  • Different fixation protocols may be required for different tissue types in IHC

  • Antigen retrieval methods significantly impact phospho-epitope detection

  • Consider using signal amplification methods for low abundance targets

How can researchers validate the specificity of Phospho-TOP2A (S1525) antibody signals?

Validation is critical for ensuring reliable results with phospho-specific antibodies:

• Essential controls:

  • Lambda phosphatase treatment of duplicate samples

  • Use of cells expressing S1525A mutant TOP2A as negative control

  • Peptide competition with phosphorylated vs. non-phosphorylated peptides

  • Knockdown/knockout of TOP2A to confirm signal specificity

• Validation across applications:

  • Compare results across multiple detection methods (WB, IHC, IF)

  • Use alternative antibodies targeting the same phospho-epitope when available

  • Consider orthogonal detection methods (mass spectrometry)

• Biological validation:

  • Verify expected cell cycle-dependent changes in S1525 phosphorylation

  • Confirm altered phosphorylation following treatment with kinase inhibitors (CDC7/DBF4 inhibitors, PLK1 inhibitors)

  • Check for expected cellular localization patterns

What are the appropriate experimental controls when studying TOP2A S1525 phosphorylation in different research models?

Proper controls ensure reliable and interpretable results:

• For cell line studies:

  • Include asynchronous and synchronized populations to account for cell cycle effects

  • Use kinase inhibitors targeting known S1525 kinases as negative controls

  • Compare wild-type cells with those expressing TOP2A S1525A or S1525D/E mutants

• For tissue analyses:

  • Include both tumor and adjacent normal tissues when studying cancer samples

  • Use tissues known to have high vs. low TOP2A expression as reference points

  • Consider developmental stage-specific controls for studies in embryonic tissues

• For animal model experiments:

  • TOP2A-deficient mouse models have shown impaired fertility, providing important phenotypic controls

  • When using adenoviral delivery of TOP2A-interfering constructs, include scrambled sequence controls

  • Time-course analyses may be necessary to capture dynamic changes in phosphorylation status

How can Phospho-TOP2A (S1525) antibodies contribute to understanding cancer drug resistance mechanisms?

TOP2A is a target for several anticancer drugs, and its phosphorylation status may contribute to drug sensitivity:

• Research applications:

  • Monitor S1525 phosphorylation status in drug-sensitive vs. resistant cell lines

  • Evaluate whether S1525 phosphorylation correlates with response to TOP2 poisons (etoposide, doxorubicin)

  • Determine if altering S1525 phosphorylation can re-sensitize resistant cells

• Methodological approaches:

  • Develop phosphorylation-specific biomarker assays for patient stratification

  • Combine phospho-TOP2A detection with functional assays of drug-induced DNA damage

  • Screen for compounds that modulate S1525 phosphorylation as potential resistance modifiers

• Emerging research directions:

  • Investigate the relationship between different TOP2A phosphorylation sites in drug response

  • Explore combination therapies targeting both TOP2A and its regulatory kinases

  • Develop computational models predicting drug response based on phosphorylation patterns

What recent advances in understanding the biological significance of TOP2A S1525 phosphorylation should researchers be aware of?

Recent research has expanded our understanding of S1525 phosphorylation:

• Cell cycle regulation:

  • S1525 phosphorylation, along with S1213, controls the timing of TOP2A recruitment at centromeres

  • This phosphorylation is part of the G2/M decatenation checkpoint mechanisms

  • Multiple kinases (CDC7/DBF4, PLK1, CKII, p38γ) have been implicated in S1525 phosphorylation

• Cancer biology:

  • TOP2A expression correlates with poor prognosis in multiple cancer types

  • Phosphorylation status at various sites, including S1525, may influence cancer progression

  • The link between cancer-associated fibroblast infiltration and TOP2A expression suggests complex tumor microenvironment interactions

• Structural insights:

  • The C-terminal domain containing S1525 is intrinsically disordered but plays critical regulatory roles

  • S1525 is located within the ChT (C-terminal) region (amino acids 1500-1531)

  • Despite not affecting catalytic activity directly, S1525 phosphorylation influences protein-protein interactions and localization

How might technological advances improve the detection and analysis of TOP2A S1525 phosphorylation in research settings?

Emerging technologies show promise for enhancing phosphorylation studies:

• Advances in antibody technology:

  • Development of recombinant phospho-specific antibodies with improved batch-to-batch consistency

  • Single-domain antibodies (nanobodies) with enhanced specificity for phospho-epitopes

  • Multiplexed detection systems allowing simultaneous analysis of multiple phosphorylation sites

• Imaging innovations:

  • Super-resolution microscopy to precisely locate phosphorylated TOP2A at centromeres and other cellular structures

  • Live-cell phospho-sensors to monitor S1525 phosphorylation dynamics in real-time

  • Correlative light and electron microscopy approaches to link phosphorylation status with ultrastructural features

• "Omics" approaches:

  • Phosphoproteomics workflows with improved sensitivity for detecting low-abundance modifications

  • Integration of phosphorylation data with other PTMs to understand combinatorial regulation

  • Systems biology approaches linking phosphorylation patterns to functional outcomes

What best practices should researchers follow when designing experiments involving Phospho-TOP2A (S1525) antibodies?

To ensure robust and reproducible results:

• Experimental design considerations:

  • Always include appropriate controls (phosphatase treatment, mutant cell lines)

  • Consider cell cycle effects in all experimental designs

  • Use multiple detection methods when possible to confirm findings

  • Document detailed protocols, including antibody validation steps

• Technical recommendations:

  • Optimize antibody concentration for each application and sample type

  • Maintain consistent sample preparation procedures, especially regarding phosphatase inhibitors

  • Consider the intrinsically disordered nature of the C-terminal domain when designing experiments

  • Be aware that S1525A mutations may lead to increased protein expression levels

• Data interpretation guidelines:

  • Distinguish between correlation and causation when linking phosphorylation to functional outcomes

  • Consider the multi-kinase regulation of S1525 when interpreting inhibitor studies

  • Acknowledge the limitations of your experimental system and antibody specificity